Injections Although studies investigating BPC 157 have demonstrated therapeutic potential, most of these analyses have been performed in animal models
Also verify renewal and cancellation terms
Low IGF-1 typically indicates insufficient growth hormone, while elevated levels may suggest excess growth hormone activity
When combined with the appetite suppression from GLP-1 medication, some users may eat even less because they simply are not hungry
Annual Costs (2025) Retail Pharmaceutical (Wegovy/Mounjaro as proxies): Without insurance: $12,000-16,800/year With insurance coverage: $1,200-3,600/year (copays) Retatrutide will likely price similarly when approved Research Peptide Suppliers: Maintenance dose (4mg weekly): $3,600-6,000/year Higher dose (8mg weekly): $7,200-12,000/year Requires self-sourcing from suppliers like Red Fox Peptides (third-party HPLC/MS testing, 98%+ purity verification, with delivery within 2-4 days for Canadian customers) Dose Reduction Strategies Many patients successfully maintain on lower doses than required for active weight loss: Lost weight on 12mg weekly